A proposal to optimize the current stroke network models in Italy could be represented by use of tenecteplase

Neurol Sci. 2024 Jun;45(6):2905-2906. doi: 10.1007/s10072-024-07344-8. Epub 2024 Jan 25.

Authors

Manuel Cappellari¹, Andrea Zini², Danilo Toni³

Affiliations

¹ Stroke Unit, Borgo Trento Hospital, DAI di Neuroscienze, Azienda Ospedaliera Universitaria Integrata, Piazzale A. Stefani 1, 37126, Verona, Italy. manuel_cappellari@libero.it.
² Department of Neurology and Stroke Center, IRCCS Istituto di Scienze Neurologiche di Bologna, Maggiore Hospital, Bologna, Italy.
³ Emergency Department Stroke Unit, Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.

PMID: 38267602
DOI: 10.1007/s10072-024-07344-8

No abstract available

Publication types

Letter

MeSH terms

Fibrinolytic Agents* / therapeutic use
Humans
Italy
Stroke* / drug therapy
Tenecteplase* / therapeutic use
Tissue Plasminogen Activator / administration & dosage
Tissue Plasminogen Activator / therapeutic use

Substances

Tenecteplase
Fibrinolytic Agents
Tissue Plasminogen Activator